Risk factors

JAKKS Pacific depends heavily on licensing agreements, seasonal holiday sales, and a small group of key customers and licensors. The company relies on CEO Stephen Berman through March 2029 and faces significant stock volatility due to a small public float.

Heavy reliance on TiO2 sales concentration which represented 90% of revenue in 2024.

LandBridge relies heavily on WaterBridge, ConocoPhillips, and EOG Resources for revenues and operational management in the Permian Basin. The business is exposed to variable interest rates on $385.5 million of debt and environmental transition risks.

The company faces severe going concern risks requiring immediate additional capital for unproven renewable fuels and electrification metals segments. Operations rely heavily on uncertain government incentives, feedstock supplies, water rights, and unproven mineral reserves. Success depends entirely on uncommercialized technology, complex facility construction, and intense commodity price volatility.

Customer concentration and lack of long-term purchase commitments dominate MEC's operating risks.

Subscription business relies heavily on retaining and attracting paying customers for investment research products.

Plastic resin, steel, and rubber cost volatility and supplier disruptions threaten manufacturing margins.

National CineMedia faces core risks around theater attendance levels, reliance on exhibitor agreements with AMC and Cinemark, and post-bankruptcy integration.

Nine Energy Service faces significant cyclicality, commodity price volatility, and heavy dependence on onshore oil and gas completion activity. The company carries substantial debt, including $300.0 million in senior notes and an ABL credit facility. Operations are exposed to stringent environmental regulations, hydraulic fracturing restrictions, intense competition, and customer concentration risks.

NLI Holdings relies heavily on its operating subsidiaries Kronos and CompX, exposing results to TiO2 and security products markets. Debt levels, raw material costs, and global environmental regulations heavily influence the company's financial condition.

Concentration risk with top ten customers drives 51 percent of consolidated net sales.

Nuvation Bio faces heavy dependence on unapproved clinical candidates like taletrectinib and safusidenib requiring substantial additional capital. Significant debt of up to $250.0 million from Sagard constrains operational flexibility and cash flow. Preclinical and clinical trial execution, regulatory hurdles, and intense biotechnology competition threaten future commercial success.